Technical Analysis for PTN - Palatin Technologies, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.91 | -1.70% | -0.02 |
PTN closed down 1.7 percent on Wednesday, November 20, 2024, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -1.70% | |
| Lower Bollinger Band Walk | Weakness | -1.70% | |
| Inside Day | Range Contraction | -1.70% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Down 3% | about 18 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Down 2 % | about 21 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/14/2024
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Obesity Dysfunction Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Obesity Dysfunction Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.65 |
| 52 Week Low | 0.68 |
| Average Volume | 317,860 |
| 200-Day Moving Average | 1.73 |
| 50-Day Moving Average | 1.07 |
| 20-Day Moving Average | 1.13 |
| 10-Day Moving Average | 1.08 |
| Average True Range | 0.12 |
| RSI (14) | 37.11 |
| ADX | 19.12 |
| +DI | 18.93 |
| -DI | 22.67 |
| Chandelier Exit (Long, 3 ATRs) | 1.04 |
| Chandelier Exit (Short, 3 ATRs) | 1.26 |
| Upper Bollinger Bands | 1.35 |
| Lower Bollinger Band | 0.90 |
| Percent B (%b) | 0.03 |
| BandWidth | 39.99 |
| MACD Line | -0.03 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0329 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.98 | ||||
| Resistance 3 (R3) | 0.99 | 0.97 | 0.97 | ||
| Resistance 2 (R2) | 0.97 | 0.95 | 0.97 | 0.97 | |
| Resistance 1 (R1) | 0.94 | 0.94 | 0.93 | 0.94 | 0.97 |
| Pivot Point | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 |
| Support 1 (S1) | 0.89 | 0.90 | 0.88 | 0.89 | 0.86 |
| Support 2 (S2) | 0.87 | 0.89 | 0.87 | 0.86 | |
| Support 3 (S3) | 0.85 | 0.87 | 0.86 | ||
| Support 4 (S4) | 0.84 |
